

**TESTIMONY OF SARA RADCLIFFE
EXECUTIVE VICE PRESIDENT, HEALTH
BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO)
HOUSE COMMITTEE ON ENERGY AND COMMERCE,
SUBCOMMITTEE ON HEALTH
HEARING ON "FDA USER FEES 2012: HOW INNOVATION HELPS
PATIENTS AND JOBS."**

APRIL 18, 2012

Chairman Upton and Pitts, Ranking Member Waxman and Pallone, Members of the Committee, it is my privilege to provide testimony before you today. My name is Sara Radcliffe and I am Executive Vice President for Health for the Biotechnology Industry Organization (BIO). In that role, I led BIO's engagement in the Prescription Drug User Fee Act (PDUFA) technical discussions with the Food and Drug Administration (FDA) and managed BIO's involvement in the biosimilars user fee (BsUFA) technical discussions.

BIO represents over 1,100 members involved in the research and development of innovative healthcare, agricultural, industrial, and environmental technologies. The U.S. biotechnology industry is poised to be a major driver in an innovation-driven economy. Biotechnology offers real solutions to our most pressing health care needs: curing disease, reducing costs, increasing quality, and ensuring that people enjoy not only longer lives, but better and more productive lives.

PDUFA V: GETTING BACK TO BASICS FOR PATIENTS

BIO supports quick enactment of the PDUFA V recommendations as we believe they can enhance the drug development and review process through increased transparency and scientific dialogue, advance regulatory science, and strengthen post-market surveillance. Most

importantly, from the standpoint of young, innovative companies, our hope is that PDUFA V will provide patients and doctors with earlier access to breakthrough therapies.

When we began the process of organizing for our discussions of PDUFA V, we in the industry started with a simple set of principles that could provide the foundation for our discussions with FDA and other stakeholders. These were that a science-based, transparent, and well-managed review process that appropriately balances benefits and risks can enhance public trust and increase patient access to new medicines.

With these principles in mind, industry and FDA agreed upon a set of enhancements under PDUFA V that seek to reinforce FDA's review performance and get back-to-basics for patients. These proposals also have been informed by an unprecedented level of public input through workshops, meetings, and stakeholder outreach, which further strengthened the technical agreement. These enhancements include:

- **New Molecular Entity (NME) Review Program**: Historically, nearly 80% of all NME applications submitted to FDA are ultimately approved, but fewer than half are approved on the first submission¹. Sponsors and FDA can and must do better for patients. By strengthening scientific dialogue and transparency between FDA and Sponsors under the proposed review program for novel drugs and biologics, we can minimize the potential review issues that can delay patient access to needed treatments. Increased FDA-Sponsor scientific dialogue and transparency, such as a mid-cycle communication, exchange of discipline review letters and advisory committee information, and a significant new late-cycle meeting, will help to identify and resolve issues earlier in the review. This represents a significant paradigm shift in FDA's review process while

maintaining FDA's high standards for safety and efficacy. An additional two-month validation period during the review period will help to ensure FDA has all the information it needs at the beginning of the process to perform a complete review. Finally, a robust third-party evaluation will provide data on whether we have been successful in this program of leading to fewer review cycles, shorter approval times, and earlier patient access to needed treatment.

- **Enhanced Communication during Drug Development:** To help advance American innovation and promote the development of the next generation of modern medicines, FDA has also committed to a philosophy under PDUFA V that timely, interactive communication with biotechnology and life science companies during drug development is a core Agency activity. The scientific method does not operate in a vacuum, and it is critical to promote interactive, scientist-to-scientist communication between FDA and Sponsors. In the course of drug development, Sponsors sometimes have simple or clarifying questions, the responses to which could have a significant impact on the development program, but which are not extensive enough to warrant formal meetings. To obtain timely responses to such questions, Sponsors currently often have to engage in a lengthy exchange of multiple formal letters with FDA, which is an inefficient and cumbersome use of both FDA's and the Sponsor's time. For small biotechnology companies reliant on limited venture capital, these delays can create significant impediments to development programs.
- **Modernizing Regulatory Science:** Additionally, the PDUFA V agreement makes new resources available to modernize regulatory science, for example, in the areas of personalized medicine and rare disease drug research. Modern approaches to drug

development and evaluation, such as through the application of new tools for rare disease drug development, flexibility with regard to creative study designs and new endpoints, greater utilization of biomarkers and patient reported outcome tools will introduce new efficiencies in the drug development enterprise and provide FDA with additional tools to evaluate the benefits and risks of pharmaceutical products. These proposals will also integrate more structured and systematic approaches to assessing benefits and risks of therapies, and allow FDA to conduct outreach to patients and hold workshops to understand better patient perspectives on disease severity and unmet medical need.

- **Robust Drug Safety and Post-Market Surveillance Capacity:** PDUFA V continues industry's commitment to a lifecycle approach to product evaluation by strengthening FDA's post-market surveillance and benefit/risk management capacity. Earlier discussion of risk management strategies, standardized approaches to REMS, and further validation of the Sentinel Network will promote patient confidence in drug and biologics.

Under the PDUFA V agreement, industry has reinforced its commitment to a well-funded drug and biologics program that supports sound, science-based regulation consistent with FDA's public health mission. However, user fees are intended to support limited FDA activities around the drug review process and were never intended to supplant a sound base of appropriations. User fees currently account for nearly two-thirds of the cost of human drug review. We urge Congress to support FDA's mission and fund the Agency at the Administration's FY12 requested levels.

BIO SUPPORTS PASSAGE OF THE BIOSIMILARS USER FEE PROGRAM

BIO supports FDA’s ongoing implementation of a well-constructed, science-based pathway for the approval of biosimilar products. A transparent, predictable, and balanced regulatory framework for the review and approval of biosimilars, accompanied by reasonable performance goals and a dedicated, independent funding stream, will ensure that FDA can facilitate the development and evaluation of biosimilar products.

Throughout both the legislative consideration of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and ongoing FDA implementation of the pathway, BIO has articulated several key principles that will promote the development of an effective regulatory framework for biosimilar products:

- Ensuring Patient Safety
- Recognizing Scientific Differences Between Drugs and Biologics
- Maintaining the Physician-Patient Relationship
- Preserving Incentives for Innovation
- Ensuring Transparent Statutory and Regulatory Processes
- Continuing to Prioritize FDA Review and Approval of New Therapies and Cures

BIO believes that the proposed user fee program is consistent with these principles and supports Congressional enactment of the program.

FAST PROVIDES CRITICAL REFORMS TO ACCELERATED APPROVAL

The FDA's Accelerated Approval pathway allows for earlier approval of new drugs that provide a benefit for patients with serious and life-threatening diseases based on a new product’s effect on surrogate or clinical endpoints that are deemed “reasonably likely to predict clinical benefit.”ⁱⁱ

Under Accelerated Approval, FDA can approve the marketing of a drug to seriously ill patients based on earlier evidence of effect with a commitment from the sponsor to conduct further post-market studies to confirm and define the degree of clinical benefits to patients. The Accelerated Approval pathway has been a great success story, but only in part. While its applicability has been largely limited to certain disease areas (mainly cancer and HIV/AIDS) and certain situations, the pathway has stimulated an explosion of investment in innovation in those diseases, and has brought immense benefit to patients suffering from these diseases. In HIV/AIDS, for example, there are now over 20 new medicines on the market. In oncology, FDA has granted Accelerated Approval to 49 new indications for 37 novel oncology drug products since 1995.ⁱⁱⁱ BIO supports H.R. 4132, the Faster Access to Specialized Treatments (FAST) Act, introduced by Congressmen Cliff Stearns and Ed Towns, which would ensure that FDA could utilize the Accelerated Approval pathway as fully and as frequently as possible while maintaining FDA's safety and effectiveness standards, and by codifying, modernizing and expanding FDA's Accelerated Approval pathway with four targeted revisions. First, it would empower FDA to consider a broad range of surrogate and clinical endpoints, including endpoints that can be measured early in the clinical trial process, and endpoints applicable to a wider array of diseases and conditions. Second, it would encourage FDA to consider a wider array of supporting evidence, in addition to clinical trial evidence, to help inform the Agency's assessment of whether there is a reasonable basis to predict clinical benefit. Third, the bill would ensure that FDA takes into consideration the severity or rarity of the condition and the adequacy of any alternative treatments. And lastly, the bill would increase the transparency, predictability, and consistency of the review process by ensuring that FDA develop new guidance and revise existing guidance and regulations to clarify the scope and process for utilizing the expanded

Accelerated Approval pathway, including specifically for rare diseases. Nothing in this bill would alter FDA's efficacy or safety standards. These important reforms would create a robust Accelerated Approval pathway that would enable the safe and expeditious development of the next generation of modern medicines to treat particularly dire conditions.

PEDIATRIC DRUG DEVELOPMENT

The Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) have been remarkably successful in ensuring that the medications used in children are tested and labeled appropriately for their use. BPCA and PREA have generated a wealth of pediatric drug information for physicians and parents, contributing to improved health outcomes for pediatric patients. Working in tandem, BPCA and PREA have resulted in nearly 425 pediatric labeling changes since 1998, according to the FDA. Congress should recognize the success of these programs and:

- Reauthorize the existing framework and incentive for ongoing pediatric research, and
- Make the programs permanent by eliminating their sunset provisions.

The five year sunset periods for BPCA and PREA result in an uncertain regulatory environment for pediatric drug development. Since the average pediatric clinical research program spans 6 years, most clinical programs will span two reauthorization periods in which the ground-rules for pediatric research are subject to change. This uncertainty makes it difficult for companies to invest in infrastructure to support development of products for children, and practically impossible for the FDA to issue guidance to promote understanding of the current regulatory framework.

Since their enactment, BPCA and PREA, working together, have been widely acknowledged as effective in promoting pediatric drug research. There is no logical reason to continue to allow such important legislation to sunset, as the ambiguity associated with this situation has the potential for limiting or endangering the pediatric research infrastructure that companies have been endeavoring to build and expand. BIO supports H.R 4274, the BPCA and PREA Reauthorization Act and thanks Congressman Mike Rogers, Congresswoman Anna Eshoo, Congressman Ed Markey and others on their championship of this important issue.

REFORM OF ADVISORY COMMITTEE CONFLICT OF INTEREST POLICIES

As a pre-eminent science-based regulatory agency, it is critical that FDA have access to the most knowledgeable and most qualified scientific minds to help inform key public health decisions and evaluate the safety and effectiveness of innovative new cures and treatments for patients. BIO thanks Representative Burgess for his work on this issue and for introducing legislation that will enhance FDA's ability to empanel highly-qualified external scientific advisors, while maintaining the highest levels of integrity for these proceedings.

In recent years, arbitrary limits and unnecessarily restrictive interpretations of conflict of interest rules have created barriers that have prevented FDA from consistently recruiting highly qualified scientific advisors. Consequently, advisory committee vacancies are at an all-time high, the quality of the scientific discourse on such panels has suffered, and FDA has at times had to rely on scientific advice from panel members lacking relevant expertise, particularly with respect to rare diseases and cutting-edge technologies where the pool of available experts can be quite small.

BIO believes that FDA should have greater flexibility and discretion to select the most appropriate advisors, consistent with the rules that apply to other federal agencies. Such changes will help to ensure that FDA decisions are informed by the best available scientific experts and in the best interest of patients.

FDA MISSION STATEMENT

FDA's mission, as amended by the Food and Drug Administration Modernization Act of 1997 and set forth in section 903 of the Federal Food, Drug, and Cosmetic Act (FFDCA), is to promote and protect the public health. However, the FDA mission statement does not reflect the Agency's critical role in incorporating modern scientific advances into review practices to ensure that innovative treatments and therapies are made available to the patients who need them.

The pathway for such long-sought health technology advances as personalized medicine, health applications of nanotechnology, and other cutting-edge developments to reach patients and to improve healthcare in the United States goes through FDA. The Agency has a critical role in facilitating healthcare innovation, but this fact is not formally and forcefully recognized in FDA's legislative mandate. BIO applauds Congressman Mike Rogers for introducing legislation and advancing a dialogue on updating the FDA's mission for the 21st century.

SUPPLY CHAIN INTEGRITY & ADOPTION OF A NATIONAL PHARMACEUTICAL TRACEABILITY SYSTEM

Due to the nature of the United States' closed and highly regulated pharmaceutical supply chain, American patients have high confidence in the integrity of the drugs and biologics they are prescribed. BIO member companies believe the quality and safety of their products is their responsibility to the patients they serve, and is their first priority. BIO supports the initiatives

that FDA has already implemented to expand the Agency's global presence through foreign offices; expand the foreign inspectorate and part of a risk-based inspectional strategy; and modernize registration and facility tracking systems and information technology infrastructure.

This Committee has also been examining granting the Agency several new regulatory authorities to further secure the supply chain and BIO looks forward to working with the Committee to further strengthen FDA's import programs and oversight. BIO is supportive of well crafted proposals to increase penalties for criminal counterfeiters and adulterers, provide FDA with authority to detain or destroy known counterfeits at our ports, modernize FDA's facility registration and tracking systems, and better leverage the resources of established international regulatory authorities through joint inspections.

In addition to enhancing oversight over the "upstream" supply chain for pharmaceutical ingredients, it is critical to make enhancements to the "downstream" domestic supply chain for finished pharmaceutical products. BIO supports the establishment of strong, uniform, national standards for serialization and tracing systems, rather than relying on the emerging patchwork of individual state mandates. In this case, BIO believes that the Congress should enact laws governing drug product serialization and traceability systems that regulators can leverage to hold supply chain members accountable for ensuring that legitimate product reaches the patient. A national system using existing and proven technologies would best protect supply chain integrity and patient safety.

Specifically, this approach would standardize efforts nationwide and provide immediate measures to increase supply chain security. Such an approach would enable the identification and adoption of a consensus standard for a traceability system and establish the foundational

building blocks and scalable infrastructure to facilitate additional system advancements. Such a system should be sufficiently flexible to allow the end-state to reflect the realization of the project's goal—facilitating the identification, and preventing the introduction, of counterfeit, diverted, substandard, adulterated, misbranded or expired drugs from the supply chain and improving the efficiency and effectiveness of recalls.

CONCLUSION

Thank you for the opportunity to offer BIO's support for the "UFA" Package. We believe that these are common sense recommendations that will help advance innovative new cures for patients. We call on Congress to fully support FDA's appropriated budget and to pass PDUFA V as expeditiously as possible. I would be pleased to answer any questions from the committee.

ⁱ FY10 PDUFA Performance Report, p.4,
<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/UCM243358.pdf>

ⁱⁱ 21 C.F.R. § 314.500; 21 C.F.R. § 601.40

ⁱⁱⁱ Dr. Paul Kluetz. ODAC. February 8, 2011, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)